Exploration of biomarkers for predicting the prognosis of patients with ...
The expression of CCL18 in diffuse large B cell lymphoma and its mechanism research, Cancer biomarkers: section A of disease markers 2018;21 (4):925-34. 10.3233/cbm-171097.
Abstract Diffuse large B-cell lymphoma (DLBCL) represents a group of tumors characterized by substantial heterogeneity in terms of their pathological and biological features, a causal factor of their varied clinical outcome. This variation has persisted despite the implementation of rituximab in treatment regimens over the last 20 years. In this context, prognostic biomarkers are of great ...
Exploration of biomarkers for predicting the prognosis of patients with ...
Background As one distinct origin of hematological malignancies, diffuse large B-cell lymphoma (DLBCL) has caused a major public health problem. However, the molecular mechanisms that underlie this association have not been clearly elucidated. To improve this situation, it is urgent to explore disease-specific diagnostic biomarkers and mechanisms. Methods Three microarray datasets (GSE25638 ...
In this study, the expression levels of ATF6 and pS6K in diffuse large B-cell lymphoma (DLBCL) were strongly correlated with several clinical indicators of poor prognosis .
Diffuse large B
Furthermore, visual representations like the one above help us fully grasp the concept of Biological Markers For Diffuse Large B Cell Lymphoma Prognosis.
Diffuse large B-cell lymphoma (DLBCL) is clinically and biologically heterogeneous. R-CHOP remains the frontline standard, with polatuzumab-R-CHP conferring a subgroup-dependent progression-free survival gain, yet early relapse and primary refractoriness persist. Classical risk indices, especially IPI and revised versions, retain benchmark value but only partially capture adverse biology. This ...
Diffuse large B cell lymphoma (DLBCL) is the most prevalent subtype of aggressive lymphoma , characterized by significant clinical and molecular heterogeneity. 1 Approximately 20%-50% of patients with DLBCL exhibit resistance to standard immunochemotherapy or experience relapse after achieving complete response, emphasizing the necessity of ...
Wang et al. develop a clinical-imaging-multi-omics prognostic index for diffuse large B cell lymphoma by integrating quantitative PET/CT biomarkers, genetic subtypes, and clinical risk factors. By analyzing large cohorts of patients, key biomarkers—total metabolic tumor volume and lactate dehydrogenase—that reflect immunosuppressive microenvironments and tumor proliferation were identified.
Introduction Diffuse large B-cell lymphoma (DLBCL) is the most common type of adult non-Hodgkin lymphoma (NHL), accounting for 30% to 40% of all NHL cases, which represents a high heterogeneity in histological, immunohistochemical, and molecular characteristics ( 1 - 3 ). Prognosis assessment of DLBCL largely relies on traditional clinical-pathological scoring systems, such as the ...
Prognostic factors for diffuse large B
Over the past 2 decades, improved insights into large B-cell lymphomas , in terms of molecular subtyping, prognostic factors, and biologic heterogeneity, have led to refinement of disease classification and development of novel therapeutic approaches.
Abstract Background Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma . The aim of this study was to comprehensively analyze the clinical, cytomorphological, and flow cytometry characteristics of DLBCL patients, with a focus on bone marrow involvement (BMI), to identify novel prognostic factors.
